Syra Health Corp. Files 8-K on Officer Changes and Other Events
Ticker: SYRA · Form: 8-K · Filed: Dec 18, 2025 · CIK: 1922335
| Field | Detail |
|---|---|
| Company | Syra Health Corp (SYRA) |
| Form Type | 8-K |
| Filed Date | Dec 18, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001, $251,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-changes, board-of-directors
TL;DR
Syra Health Corp. filed an 8-K on 12/18/25 detailing officer changes and other corporate events.
AI Summary
Syra Health Corp. filed an 8-K on December 18, 2025, reporting on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. The filing also covers other events and financial statements/exhibits, with the earliest event reported being December 15, 2025. The company is incorporated in Delaware and its principal executive offices are located in Carmel, Indiana.
Why It Matters
This 8-K filing indicates potential shifts in leadership or governance at Syra Health Corp., which could impact the company's strategic direction and operational stability.
Risk Assessment
Risk Level: medium — Changes in officers or directors, as reported in an 8-K, can signal internal shifts that may carry operational or strategic risks.
Key Players & Entities
- Syra Health Corp. (company) — Registrant
- December 15, 2025 (date) — Earliest event reported
- December 18, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- Carmel, IN (location) — Principal executive offices
FAQ
What specific officer positions were affected by the changes reported in the 8-K?
The filing indicates changes related to 'Departure of Directors or Certain Officers' and 'Appointment of Certain Officers', but the specific positions are not detailed in the provided text.
Were there any new directors elected to the Syra Health Corp. board?
The filing mentions the 'Election of Directors' as an item of report, suggesting that director elections may have occurred or are being reported.
What types of compensatory arrangements for officers are being disclosed?
The filing lists 'Compensatory Arrangements of Certain Officers' as an item of report, indicating that details regarding these arrangements are being disclosed.
Are the financial statements and exhibits filed with this 8-K preliminary or audited?
The filing lists 'Financial Statements and Exhibits' as an item, but the nature (preliminary or audited) of these financial statements is not specified in the provided text.
What is the significance of the 'Other Events' section in this 8-K filing?
The 'Other Events' section is a catch-all for significant corporate events that do not fit into the other standard 8-K item categories, and its specific content would require reviewing the full filing.
Filing Stats: 1,182 words · 5 min read · ~4 pages · Grade level 11 · Accepted 2025-12-18 09:48:37
Key Financial Figures
- $0.001 — hich registered Class A Common Stock, $0.001 par value SYRA OTCQB Indicate by
- $251,000 — led to receive an annual base salary of $251,000 and an annual performance bonus with a
Filing Documents
- form8-k.htm (8-K) — 47KB
- ex10-1.htm (EX-10.1) — 202KB
- ex99-1.htm (EX-99.1) — 16KB
- 0001493152-25-028301.txt ( ) — 467KB
- syra-20251215.xsd (EX-101.SCH) — 3KB
- syra-20251215_lab.xml (EX-101.LAB) — 33KB
- syra-20251215_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
02
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 15, 2025, the Board of Directors of Syra Health Corp. (the "Company") appointed Gregory R. Alexander as Chief Executive Officer of the Company and entered into an employment agreement with Mr. Alexander, effective January 5, 2026 (the "Alexander Employment Agreement"). Under the terms of the Alexander Employment Agreement, Mr. Alexander is entitled to receive an annual base salary of $251,000 and an annual performance bonus with a target amount equal to 30% of his annual base salary based upon the Board's assessment of Mr. Alexander's and the Company's attainment of goals as set by the Board in its sole discretion. In accordance with the Alexander Employment Agreement, Mr. Alexander will also be granted 110,537 restricted stock units, 20% of which vest one year after date of grant and the remainder which vest equally over 4 years beginning one year after date of grant. Additionally, he will be granted stock options to purchase 257,920 shares of Class B common stock with 20% vesting on December 31, 2026 and the remainder vesting equally on an annual basis through December 31, 2030 as well as 368,458 performance stock units, subject to achievement of performance targets to be determined. In addition, the Alexander Employment Agreement contains non-competition and non-solicitation provisions. Pursuant to the terms of the Alexander Employment Agreement, if Dr. Alexander's employment is terminated by the Company for cause or as a result of Mr. Alexander's death or permanent disability, or if Mr. Alexander terminates his employment agreement voluntarily, Mr. Alexander will be entitled to receive a lump sum equal to (i) any portion of unpaid base compensation then due for periods prior to termination, (ii) any bonus earned but not yet paid through the date of his termination, and (iii) all business
01
Item 8.01 Other Events. On December 18, 2025, the Company issued a press release announcing the appointment of Mr. Alexander as Chief Executive Officer. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. Item 9.01
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. 10.1 Employment Agreement between Gregory R. Alexander and Syra Health Corp. effective as of January 5, 2026. 99.1 Press Release of Syra Health Corp. dated December 18, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SYRA HEALTH CORP. Date: December 18, 2025 By: /s/ Priya Prasad Priya Prasad Interim Chief Executive Officer